AMENDMENTS TO THE CLAIMS

1. (cancelled)

2. (canceled)

3. (cancelled)

4. (cancelled)

5. (cancelled)

6. (cancelled)

7. (cancelled)

8. (cancelled)

9. (currently amended) A spontaneously dispersible pharmaceutical composition for oral administration comprising
(a) up to 20% by weight of N-benzoyl-staurosporine,
(b) 5 to 50% by weight of a hydrophilic component,
(c) 5 to ~~810~~ 80% of a surfactant or surfactant mixture,
(d) 5 to 85% of a lipophilic component, and
(e) 0.05 to 5% of an additive.

10. (withdrawn) A method of treatment for treating subjects in need of N-benzoyl-staurosporine therapy comprising administering a dispersible pharmaceutical composition according to claim 1 to a subject in need of such treatment.

11. (currently amended) A pharmaceutical composition according to claim 9 wherein said composition provides in a subject which has been been dosed said oral composition, ~~for oral administration comprising N-benzoylstaurosporine and having~~
(a) a variability of bioavailability levels of N-benzoylstaurosporine of from 5 to 17%;
(b) an AUC (0-48h)/dose value (in (h·nmol/L)/(mg/kg)) of from 380 to 2000, or
(c) a C_{max}, dose value (in (nmol/L)/(mg/kg)) of from 60 to 310, upon administration of a dose (in mg/kg) of N-benzoylstaurosporine.

12. (withdrawn)

13. (withdrawn)